intravitreal and intracameral bevacizumab in neovascular glaucoma/: an interventional case series

purpose: to evaluate the effects of intravitreal and intracameral injection of bevacizumab in patients with neovascular glaucoma (nvg).   methods: this interventional case series was conducted on 40 eyes of 40 patients with neovascular glaucoma. data included the extent of iris (nvi) and angle neovascularization (nva), peripheral anterior synechia (pas), and intraocular pressure (iop). following standard nvg treatment, 1.5 and 1 mg of bevacizumab were injected intravitreally and intracamerally, respectively. six weeks after injection, the same procedure was repeated. results: intraocular pressure decreased significantly from 40.15±18.33 to 29.27±15.07 mmhg (p<0.001). nvi and nva were eliminated in 97.5% and 100% of patients, respectively. no significant change was seen in best corrected visual acuity (bcva). after the injection, hyphema occurred only in one eye. conclusion: intravitreal and intracameral injection of bevacizumab is an effective complementary treatment for reducing nvi and nva and hence iop in nvg.